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Abstract
Protein kinases are the most common protein domains implicated in cancer, where somatically acquired mutations are
known to be functionally linked to a variety of cancers. Resequencing studies of protein kinase coding regions have
emphasized the importance of sequence and structure determinants of cancer-causing kinase mutations in understanding
of the mutation-dependent activation process. We have developed an integrated bioinformatics resource, which
consolidated and mapped all currently available information on genetic modifications in protein kinase genes with
sequence, structure and functional data. The integration of diverse data types provided a convenient framework for kinome-
wide study of sequence-based and structure-based signatures of cancer mutations. The database-driven analysis has
revealed a differential enrichment of SNPs categories in functional regions of the kinase domain, demonstrating that a
significant number of cancer mutations could fall at structurally equivalent positions (mutational hotspots) within the
catalytic core. We have also found that structurally conserved mutational hotspots can be shared by multiple kinase genes
and are often enriched by cancer driver mutations with high oncogenic activity. Structural modeling and energetic analysis
of the mutational hotspots have suggested a common molecular mechanism of kinase activation by cancer mutations, and
have allowed to reconcile the experimental data. According to a proposed mechanism, structural effect of kinase mutations
with a high oncogenic potential may manifest in a significant destabilization of the autoinhibited kinase form, which is likely
to drive tumorigenesis at some level. Structure-based functional annotation and prediction of cancer mutation effects in
protein kinases can facilitate an understanding of the mutation-dependent activation process and inform experimental
studies exploring molecular pathology of tumorigenesis.
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Introduction
A central goal of cancer research involves the discovery and
functional characterization of the mutated genes that drive
tumorigenesis [1]. The Human Genome Project has provided
researchers with unprecedented insights into the structure and
organization of genes. Large-scale resequencing and polymor-
phism characterization studies have subsequently focused on the
identification and cataloguing of naturally occurring gene and
sequence variation [2–5]. The Cancer Genome Atlas and related
DNA sequencing initiatives have specifically investigated the
genetic determinants of cancer [6]. These studies have determined
that only a fraction of genetic alterations contributing to
tumorigenesis may be inherited, while somatically acquired
mutations can contribute decisively during the progression of a
normal cell to a cancer cell. Protein kinases play a critical role in
cell signaling and have emerged as the most common protein
domains that are implicated in cancer [7–11]. Although the kinase
catalytic domain is highly conserved, protein kinase crystal
structures have revealed considerable structural differences
between closely related active and highly specific inactive forms
of kinases [12–17]. Evolutionary conservation and conformational
plasticity of the kinase catalytic domain allow for a dynamic
equilibrium between active and inactive kinase forms, which can
facilitate regulation of the catalytic activity [15–17]. There are
more than 500 protein kinases encoded in the human genome and
many members of this family are prominent therapeutic targets for
combating diseases caused by abnormalities in signal transduction
pathways, especially various forms of cancer [18–22].
The complete sequencing of the human genome and high-
throughput generation of genomic data have opened up avenues
for a systematic approach to understanding the complex biology of
cancer and clinical targeting of activated oncogenes. Large-scale
tumor sequencing studies have identified a rich source of naturally
occurring mutations in the protein kinase genes with many being
simple single nucleotide polymorphisms (SNPs) [23–32]. A subset
of these SNPs could occur in the coding regions (cSNPs) and lead
to the same polypeptide sequence (synonymous SNPs, sSNPs) or
result in a change in the encoded amino acid sequence
(nonsynonymous coding SNP, nsSNPs). Resequencing studies of
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the kinase coding regions in tumors have classified tumor-
associated somatic mutations revealing that only a small number
of kinase mutations may contribute to tumor formation (known as
cancer driver mutations) while the majority could be neutral
mutational byproducts of somatic cell replication (known as
passenger mutations) [23–28]. While protein kinases have a
prominent role in tumorigenesis, commonly mutated protein
kinases in cancer appeared to be the exception to the rule and
most of kinase driver mutations are expected to be distributed
across many protein kinase genes [27]. Cancer mutations in
protein kinases could often exemplify the phenomenon of
oncogene addiction whereby, despite the accrual of numerous
genetic alterations over the maturation of a tumor, cancer cells
could remain reliant upon particular oncogenic pathways and may
become addicted to the continued activity of specific activated
oncogenes [33,34]. The dominant oncogenes that confer the
oncogene addiction effect include ABL, EGFR, VEGFR, BRAF,
FLT3, RET, and MET kinase genes [34].
The recent discovery of lung cancer mutations in the EGFR
kinase domain [35–37] and their differential sensitivity to EGFR
inhibitors have suggested that genetic alterations may be associated
with structural changes, rendering tumors sensitive to selective
inhibitors. Structural determinations of the EGFR [38–41] and
ABL cancer mutants [42,43] have suggested that molecular
mechanisms of kinase activation by cancer mutations and activity
signatures of cancer drugs may be associated with the dynamics of
functional transitions between inactive and active kinase forms.
Biophysical modeling of protein kinase structure and dynamics has
revealed important mechanistic features of kinase activation at
atomic resolution. Molecular dynamics (MD) simulations of large-
scale conformational transitions have been performed for many
therapeutically important protein kinases, including HCK kinase
[44], adenylate kinase [45], Src kinase [46–51], cyclin-dependent
kinase 5 (CDK5) [52], ABL kinase [53], KIT kinase [54] EGFR,
RET and MET kinase domains [55–57]. These studies have
suggested that cancer mutations can have a subtle, yet profoundly
important functional affect not only on local conformational
changes at the mutational site, but also on allosteric regulation
and cooperative interactions in signal transduction networks
[58,59]. According to the proposed mechanism of kinase
activation, structural effect of cancer mutations could manifest in
shifting the dynamic equilibrium between inactive and active kinase
forms towards a constitutively active kinase, thereby causing
deleterious consequences for kinase regulation.
Cancer biology studies of protein kinase genes have integrated
genetic, structural and functional approaches to characterize
underlying molecular signatures of cancer mutations. High-through-
put DNA sequence analysis and functional assessment of candidate
cancer mutations in the tyrosine kinase genes have identified point
mutations in the conserved hot spots from the activation loop in
leukemia-associated tyrosine kinases [60–63]. A high-throughput
platform has been used to interrogate the entire FLT3 coding
sequence in AML patients and experimentally test the functional
consequences of each candidate tumorigenic allele [63]. These
studies have indicated that rare driver variants could often occur at
frequencies indistinguishable from passenger mutations. As a result,
functional analysis of candidate mutations identified in genome-wide
screens can be ultimately required to determine which mutations
contribute to cell transformation. Computational approaches, when
combined with structural and functional studies, have also facilitated
the identification and prediction of candidate cancer genes and
individual alleles contributing to tumorigenesis [64–67].
Bioinformatics tools were recently developed to distinguish
between driver and passenger nsSNPs [68,69]. Though quite
powerful, generalized prediction methods may fail to achieve the
sensitivity and specificity attainable by prediction models tailored to
individual protein families. We have developed kinase-targeted
machine learning models that focused on nsSNPs in protein kinases
by leveraging known sequence-based and structure-based protein
kinase features to identify patterns in residues and sequence motifs
harboring functionally relevant variations [70–72]. The developed
support-vector machine (SVM) method has been shown to
differentiate between disease-associated nsSNPs and neutral nsSNPs
with ,80% accuracy [70]. These findings have suggested that
the predictive power of machine learning models in assessing
functionally important mutations can be significantly enhanced by
selecting informative attributes characteristic of a specific protein
family. Furthermore, we have found that kinase regions harboring a
large number of cancer mutations in multiple protein kinases could
contain a high proportion of the predicted driver mutations, while
kinase subdomains devoid of cancer mutations were more likely to
contain passenger mutations [71,72]. These results have suggested
that biological characteristics and functional consequences separat-
ing cancer driver mutations from passenger mutations in protein
kinases may differ from those separating disease-associated from
neutral nsSNPs across the entire genome.
The growing body of genetic, molecular and functional
information about protein kinases genes, combined with their
prominent role as therapeutic targets for cancer intervention have
produced an unprecedented explosion of diverse data. A large
amount of information about genetic modifications in protein kinase
families has been accumulated in different sources, including
PupaSNP [73], dbSNP database [74], Online Mendelian Inheri-
tance in Man (OMIM) from National Center for Biotechnology
Information (NCBI) [75,76], KinMutBase [77,78], BTKbase [79],
Human gene mutation database (HGMD) [80,81], Catalogue of
Somatic Mutations in Cancer database (COSMIC) [82], Protein
Kinase Resource (PKR) [83], and Mutations of Kinases in Cancer
(MoKCa) [84]. While current databases and information portals
have accumulated a large amount of information on kinase SNPs,
there is a growing need for integration and comprehensive mapping
of diverse data categories on protein kinase genes within a central
resource.
In this work, we introduce Composite Kinase Mutation Database
(CKMD), a single repository and integrated bioinformatics resource
that consolidated and unequivocally mapped all currently available
information on genetic variations in protein kinase genes with
sequence, structural and functional data. CKMD and web-based
resource are freely available at http://verklab.bioinformatics.ku.
edu/database/. The functionality and capabilities of CKMD portal
can allow for robust functional annotation of protein kinase genes
and enable kinome-wide prediction and structure-functional
analysis of cancer mutations. The database-driven analysis of
sequence and structure-based signatures of kinase SNPs has clarified
salient aspects of sequence conservation patterns and structural
profiles of cancer-causing mutations, including the emergence of
structurally conserved tumorigenic hotspots across multiple protein
kinases. Furthermore, structural modeling and energetic analysis of
kinase cancer mutations, which constitute the largest mutational
hotspot, have provided useful insights into a common mechanism of
kinase activation.
Results
Sequence-Structure Classification and Mapping of Kinase
SNPs
The integration and mapping of diverse data types in CKMD
provided a convenient framework for kinome-wide analysis of
Cancer Mutation Hotspots
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sequence-based and structure-based signatures of cancer muta-
tions. Genetic variations in protein kinase genes are widely spread
across both phylogenetic and structural space, and only a subset of
all SNPs could be directly mapped to the kinase catalytic domain.
We began by analyzing the distribution of various SNPs categories
that could be mapped onto the 12 functional subdomains (SDs) of
the kinase catalytic core [7] (Figure 1). Structural mapping of
sSNPs resulted in a uniform coverage of kinase subdomains,
showing only a weak preference towards SD II which has no
obvious functional role in kinase regulation (Figure 2A). In
contrast, the distribution of nsSNPs highlighted the preferential
bias towards specific functional regions. Indeed, functionally
important P-loop (SD I), hinge region (SD V), catalytic loop (SD
VIB), and especially activation loop (SD VII) along with the
downstream P+1 loop region (SD VIII) tend to be more densely
populated (Figure 2B). The P+1 segment links the subdomains in
Figure 1. Functional Subdomains of the Kinase Catalytic Core. The kinase catalytic domain was subdivided into 12 subdomains (SD) using
the ABL kinase crystal structure (pdb entry 1IEP) as the reference for defining the residue ranges as follows : SD I:242–261(P-loop region); SD2 :262–
278; SD3:279–291(aC-helix); SD4:292–309; SD5:310–335 (hinge region); SD6A:336–356; SD6B357–374 (catalytic loop); SD7:375–393 (activation loop) ;
SD8:394–416 (P+l loop); SD9:417–438; SD10:439–461; SD11:462–480; SD12:481–498. The alignment of functional subdomains for protein kinase genes
was done using structure-informed multiple sequence alignment.
doi:10.1371/journal.pone.0007485.g001
Figure 2. The Distribution of SNPs Types across Functional Subdomains of the Kinase Catalytic Core. The distribution of kinase sSNPs is
shown in panel (A) and the distribution of sSNPs is presented in panel (B).
doi:10.1371/journal.pone.0007485.g002
Cancer Mutation Hotspots
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the C-terminal lobe with the ATP and substrate binding regions in
the N-terminal lobe. Moreover, the P+1 loop is directly connected
to the F-helix, which serves as a central scaffold in the assembly of
active kinase form [85–87].
The kinase catalytic domain harbors a significant number of
nsSNPs falling into three major categories: common and likely
neutral nsSNPs, inherited disease-causing nsSNPs, and cancer-
causing (somatic) nsSNPs. We analyzed evolutionary conservation
patterns among these three different categories of kinase nsSNPs
(Figure 3). A measure of conservation was derived from the
absolute value of the substitution position-specific evolutionary
conservation score, termed ‘‘subPSEC,’’ which was obtained by
aligning a given protein against a library of Hidden Markov
Models (HMM) representing distinct protein families [88,89]. The
score was defined as -|ln(Paij/Pbij)|, where Paij is the probability of
observing amino acid a at position i in HMM j. According to the
PANTHER website [89], a score of -3 would correspond to an
estimated 50% probability that the SNP may be a disease causing
variant. The SNPs conservation profiles for kinase genes could be
described as the absolute value of subPSEC score, where the
higher the score, the greater the degree of evolutionary
conservation. The distribution of common nsSNPs was biased
towards a lower level of conservation, as would be expected for
neutral variants with little or no functional significance. Cancer-
associated nsSNPs appeared to fall into positions with a higher
level of conservation than common nsSNPs, yet could be as
conserved as disease-causing nsSNPs (Figure 3A). This analysis
indicated that either cancer-associated nsSNPs may not necessarily
fall into evolutionary highly conserved positions, or the distribu-
tion may be skewed towards a lower conservation level by cancer
variants of no functional consequence (passenger mutations).
Using a recently developed SVM-based method capable of
predicting functionally important cancer mutations [70,71], we
compared the evolutionary conservation distributions of cancer
driver mutations and passenger mutations at different levels of
conservation (Figure 3B). Although the predicted cancer driver
mutations did fall at the positions exhibiting slightly higher
conservation level, as compared to the passenger mutations, the
difference was rather modest. Hence, it appeared that cancer
mutations in protein kinases may not display strong sequence
conservation signals and consequently, functional importance of
kinase genetic variants may not be directly related with their
evolutionary conservation.
We also analyzed molecular determinants of genetic variations
in protein kinases utilizing CKMD resource for a comprehensive
structural mapping of nsSNPs onto the kinase catalytic core. The
database-driven analysis revealed a differential enrichment of
SNPs categories in functional regions of the kinase domain
(Figures 4, 5). Common nsSNPs tend to be randomly distributed
within the catalytic core, only sparsely populating functional
segments of the catalytic core, such as the catalytic or activation
loops, whereas these nsSNPs more densely occupy evolutionary
unconserved regions of the C-terminal tail (Figure 4A). The
disease-causing nsSNPs primarily mapped to the regions involved
in regulation and substrate binding, such as the APE-loop and the
P+1 region, as well as the catalytic loop (Figure 4B). Cancer-
associated nsSNPs tend to target regions directly involved in the
catalytic activity that are mainly localized in the P-loop, activation
loop and catalytic loop (Figures 4C). The distribution of kinase
nsSNPs across functional kinase subdomains reinforced the notion
that the kinase regions that are enriched (or devoid) of SNPs could
be markedly different across the three mutation types, with a
minimal overlap. Indeed, the distribution shows a clear preference
for cancer-causing nsSNPs to accumulate mostly in the activation
loop region (SDVII) as well as populating the P-loop (SD I)
(Figure 5A). A significant number of disease-associated nsSNPs
Figure 3. The Distribution of nsSNPs Types across Evolutionary Conservation Levels. (A) The probability distribution of common nsSNPs
(shown in blue bars), disease-causing SNPs (shown in red bars) and cancer-causing nsSNPs (shown in green bars) as a function of evolutionary
conservation level. (B) The probability distribution of cancer driver mutations (shown in blue bars) and passenger nsSNPs ( shown in red bars) as a
function of evolutionary conservation level. For both panels (A) and (B), a higher score corresponds to a higher level of conservation.
doi:10.1371/journal.pone.0007485.g003
Cancer Mutation Hotspots
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were not directly involved in the ATP binding, but rather buried
in the catalytic core. Interestingly, the P+1 loop and the residues
that anchor this pocket to the F-helix were some of the most
enriched in disease-associated mutations, but not cancer-causing
mutations. These results corroborate with previous findings
indicating that disease-associated mutations could primarily affect
the kinase regions involved in functional regulation, allosteric
interactions and substrate binding [72].
Functional differences across different mutation types could be
also reflected in the position-specific distribution of nsSNPs at the
mutational hotspots determined by the number of structurally
equivalent protein kinase positions (Figure 5B). The distribution
of common nsSNPs, that have little or no functional affect and
could be randomly distributed throughout the catalytic core, was
dominated by weakly conserved positions mutated in a single, or
two protein kinases. In contrast, the disease-causing nsSNPs tend
Figure 4. Structural Mapping of nsSNPs onto the Kinase Catalytic Domain. Structural mapping is shown for common nsSNPs (A), disease-
causing nsSNPs (B), and cancer-causing nsSNPs (C). In all panels the green coloration represents regions with a SNP frequency equivalent to what
would be expected by random chance, blue coloration represents regions that are statistically devoid of SNPs, and red coloration depicts regions that
are statistically enriched in SNPs. Enrichment of SNPs in these regions was calculated as described in the Materials and Methods section. For clarity,
the SNPs density was mapped onto a representative kinase crystal structure (EGFR, pdb entry 1M14) by projecting the multiple sequence kinase
alignment onto the protein structure.
doi:10.1371/journal.pone.0007485.g004
Figure 5. The Distribution of nsSNPs Types across Functional Subdomains of the Catalytic Core. (A) The distribution of common nsSNPs
(shown in blue bars), disease-causing nsSNPs (shown in red bars), and cancer-causing nsSNPs (shown in green bars) in the functional subdomains of
the kinase catalytic core. The expected probability of a SNP occurring in a kinase subdomain region was calculated for each SNP type as described in
the Materials and Methods section. (B) The position-specific distribution of common nsSNPs (shown in blue bars), disease-causing nsSNPs (shown in
red bars), and cancer-associated nsSNPs (shown in green bars) across different categories of structurally conserved mutational hotspots as
determined by the number of SNPs per structurally identical position.
doi:10.1371/journal.pone.0007485.g005
Cancer Mutation Hotspots
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to be concentrated at structurally equivalent positions, with a
significant excess of mutations occurring at positions mutated in
four or more different protein kinases. The position-specific
distribution of cancer nsSNPs was shifted towards a higher
number of nsSNPs per position, probably due to the selection of
tumorigenic mutational hotspots shared across multiple protein
kinases (Figure 5B).
Structural Bioinformatics Analysis of Kinase Mutational
Hotspots
Kinome-wide analysis of sequence and structure-based signa-
tures of cancer mutations, revealed that a significant number of
cancer mutations could fall at structurally equivalent positions
within the catalytic core. These structurally conserved mutations
tend to cluster into specific mutational hotspots which may be
shared by multiple kinase genes. Cancer mutation hotspots in
protein kinases are largely localized within the P-loop, hinge
region, and activation loop (Figure 6A, Table S1). Of special
interest is a spectrum of EGFR, ABL, MET, FLT3 and KIT
cancer mutations that correspond to the same structurally
conserved position in the activation loop, which appeared to be
mutated in at least 8 different kinases (Figure 6A, Table S1).
This site corresponds to the known driver mutations BRAF-V600,
FLT3-D835, KIT-D816, PDGFRa-D842, MET-D1228, EGFR-
L861, ABL-L387, and ErbB2-L869. Despite a sequence-specific
conservation pattern, many mutations at this structurally con-
served position are commonly occurring activating mutations,
including D1228H/N/V in MET [90,91], D835E/F/H/N/V/Y
in FLT3 [92,93], D816E/F/H/N/I/V/Y in KIT [94,95] and
V600D/E/G/K/L/M/R in BRAF [96]. In some cases, these
mutations could have important implications for targeted inhibitor
therapies by leading to drug resistance effects in KIT [97], BRAF
[98], EGFR [99], ABL [100], and MET [101]. Another
functionally important mutational hotspot corresponds to the
conserved gate-keeper kinase position and includes ABL-T315I,
EGFR-T790M, KIT-T670E, and PDGFRa-T674I variants
(Figure 6A, Table S1). Some of the structurally equivalent
positions could be conserved across the kinome, as the aspartate
and glycine residues from the DFG motif (corresponding to the
reference positions EGFR-D855 and EGFR-G857), as well as a
conserved glycine in the hinge region (which corresponds to the
EGFR-G796 reference position). There are examples of cancer
mutations displaying a subgroup level of conservation, including
EGFR-L858 position, which bears a conserved leucine in EGFR
and ABL kinases, or a conserved aspartate shared in FLT3, KIT,
MET, PDGFRa.
While most of the cancer driver mutations are likely to be rather
rare, it is striking that a significant number of functionally
important cancer mutants fall at structurally conserved positions
within the kinase catalytic core. Moreover, we have observed that
structurally conserved hotspots of cancer driver mutations often
bear mutations with a high oncogenic activity (Figure 6B). A
quantitative characterization of ‘‘oncogenicity’’ could be described
in a variety of ways, including cell transformation potential,
substrate utilization, and catalytic efficiency. However such data
are typically available only for a limited number of genes and
mutations and are not suitable for genome-wide analysis. We used
a convenient definition of an oncogenic potential that may be
offered by using the frequency profiles of somatic mutations in the
protein kinases genes obtained from the COSMIC repository [82].
This analysis revealed that a rather small number of somatic
Figure 6. Structurally Conserved Mutational and Oncogenic Hotspots in the Kinase Catalytic Domain. (A) Structural localization of the
conserved mutational hotspots is illustrated using the crystal structure of the active EGFR kinase (pdb entry 2J6M). The large-size red ball corresponds
to the structural position of L861, and denotes localization of the largest mutational hotspot shared in 8 different kinases. The medium-size yellow
balls correspond to structural positions of T790, D855, and G857 residues (respective mutational hotspots shared by 6 different kinases). The smaller
green ball corresponds to G796 position (5 structurally conserved kinase mutations); the cyan balls correspond to L718 and G721 positions (each
position denote residues with 4 cancer mutations); and the smallest blue ball corresponds to L858 position (3 structurally conserved kinase
mutations). Cancer mutation hotspots in protein kinases are largely localized within the P-loop, hinge region, and activation loop. See also Table S1
for a comprehensive annotation of structurally conserved mutational hotspots. (B) Structural localization of cancer driver mutations with the high
oncogenic potential is illustrated using the crystal structure of the active EGFR kinase (pdb entry 2J6M). The dominant oncogenic mutations are
BRAF-V600E, KIT-D816V, and PDGFRa-D842V which all correspond to the same structurally conserved mutational hotspot. Structural annotation of
cancer driver mutations is arranged according to their oncogenic potential as determined by the frequency of observing respective somatic
mutations in the protein kinases genes. The higher the oncogenic potential of the cancer drive, the larger the ball denoting structural position of the
respective mutation.
doi:10.1371/journal.pone.0007485.g006
Cancer Mutation Hotspots
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kinase mutations with the known oncogenic potential could
emerge with a high frequency in the mutational samples (Table
S2). Strikingly, these functionally important mutations fall into
major structurally conserved positions in the kinase catalytic
domain. Indeed, highly oncogenic mutations BRAF-V600E, KIT-
D816V, and PDGFRa-D842V belong to the largest mutational
hotspot (Figure 6B). The functional importance of oncogenic
kinase mutations from mutational hotspots such as ABL-T315I,
EGFR-L858R, and RET-M918T, is also widely recognized. For
instance, structurally conserved RET-M918T and MET-M1250T
cancer drivers are situated in the substrate binding C-lobe of the
kinase core (Figure 6B) and are known to be associated with
oncogenic activation by displaying the highest transforming
potential among known RET [102–106] and MET mutations
[107–110]. The presented analysis suggests that structurally
conserved hotspots in the kinase catalytic domain may be
statistically enriched by mutations with a high probability of being
cancer drivers. We argue that the preferential structural
localization of oncogenic mutations in the activation loop and
the substrate binding C-lobe of the kinase domain may be
determined by their strategic location critical for the kinase
autoinhibition, regulation and allosteric interactions in signal
transduction networks.
Structural and Energetic Signatures of Kinase Mutational
Hotspots
Structural modeling and energetic analysis of cancer mutation
effects can provide further insights into molecular mechanisms of
kinase activation. We employed homology modeling and MD
simulations to analyze whether structurally conserved cancer
drivers that target the same tumorigenic hotspot in the kinase
catalytic domain may also share a common activation mechanism.
Molecular modeling focused on a quantitative comparison of
MET-D1228V, MET-D1228H [90,91], FLT3-D835V, FLT3-
D835E [92,93], and KIT-D816V, KIT-D816H [94,95] mutants.
Substitutions of D835 in FLT3 and D816 in KIT result in the
constitutive activation of the receptor, this residue has been
suggested to play an important regulatory role. The crystal
structures of FLT3 [111], KIT [112] and MET kinases
[113,114] have suggested that cancer mutations may destabilize
the autoinhibited wild-type (WT) form. It is important to note that
structural modeling studies were performed to evaluate the extent
of local perturbations that could be induced by cancer mutations
on the autoinhibited kinase structure. Given the absence of high
resolution crystal structures of kinase cancer mutants and nature of
large conformational changes caused by activating mutations, we
focused on understanding local functional effects of cancer
mutations rather than attempting to make computational
predictions of the mutant structures.
Homology modeling and MD simulations of commonly occur-
ring activating mutations in this mutational hotspot revealed a
significant local reorganization of the autoinhibited kinase confor-
mation. This is reflected in the local structural variations near the
site of mutation (root mean square deviations, RMSD = 3 Å24 Å)
(Table S3). The majority of cancer mutations resulted in moderate
global changes, but considerable local structural changes near the
mutational site and in the activation loop. The results revealed that
structurally conserved FLT3-D835V (Figure 7) and KIT-D816V
mutations (Figure 8) enhanced the local protein mobility near the
mutational site and destabilized the autoinhibited kinase confor-
mation through a similar molecular mechanism. Interestingly,
FLT3-D835 and KIT-D816 participate in stabilization of the 310-
helix (Figures 7A, 8A), which includes a stretch of residues (I836,
M837, S838, D839, N841 in FLT3 and I817, K818, N819, D820
and S821 in KIT). During simulations the 310-helix rapidly
unfolded and remained in the unfolded state for both FLT3-
D835V (Figure 7B) and KIT-D816 mutants (Figure 8B). Local
perturbations induced by these mutations caused similar disruptions
in the interaction networks responsible for stabilization of the
inactive kinase form. In agreement with earlier studies [115–117],
our results confirmed that deleterious effects of FLT3-D835V and
KIT-D816V substitutions could primarily result from destabiliza-
tion of the 310-helix motif that is critical for the integrity of the
inactive kinase form. Homology modeling and MD refinement of
the EGFR-L861Q mutant, initiated from the inactive, Src-like
EGFR crystal structure (Figure 9A), reproduced conformational
changes in the activation loop leading to the active kinase form
Figure 9B). This may be attributed to a considerable incompat-
Figure 7. Structural Modeling of the FLT3-D835V Mutant. (A) The crystal structure of the autoinhibited wild-type FLT3 (pdb entry 1RJB). The
position of D835 and key conserved residues K644 and E661 are highlighted. The location of the critical 310-helix is indicated with an arrow. (B)
Structural model of FLT3-D835V cancer mutant. Structural change in FLT3-D835V position and unwinding of the 310-helix are highlighted with
arrows.
doi:10.1371/journal.pone.0007485.g007
Cancer Mutation Hotspots
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ibility of the activating mutation with the Src-like structure of the
WT EGFR. While the hydrophobic Leu-861 is packed in a
hydrophobic core of the WT structure (Figure 9A), switching to a
polar residue triggered a conformational transition of the activation
loop folding outwards, towards an active-like kinase state
(Figure 9B).
According to our recent findings [56,57], cancer mutations in
ABL and EGFR kinases, that display high oncogenic activity, may
also induce the greater differential effect on thermodynamic
stability of the inactive and active kinase forms. These energetic
factors may serve as thermodynamic catalysts of kinase activation
by cancer mutations. In line with this hypothesis, structural
signatures of the cancer mutational hotspot may manifest in
deleterious protein stability changes in the inactive state of the
enzyme, thereby promoting transitions to the constitutively active
kinase form. In the present study, we verified and expanded the
initial conjecture by analyzing structural mapping of mutational
hotspots and performing computational evaluation of protein
stability changes using CUPSAT and FOLDx methods
(Figures 10,11). Both approaches revealed a consistent trend,
whereby commonly occurring activating mutations with an
appreciable oncogenic activity resulted in a considerable destabi-
lization of the autoinhibited WT structure (Figure 10). For
example, mutations D1228H, D1228N, and D1228V in MET
from the mutational hotspot are known to have significant
oncogenic transformation effect of NIH 3T3 cells [118,119].
Accordingly, these mutations were shown to have a significant
destabilization effect on the protein structure (Figure 10).
In order to illustrate functional significance of structural effects
and concomitant protein stability changes for kinase cancer
Figure 8. Structural Modeling of the KIT-D816V Mutant. (A) The crystal structure of the autoinhibited wild-type KIT (pdb entry 1T46). The
position of D816 and key conserved residues K623 and E640 are highlighted. The location of the critical 310-helix is indicated with an arrow. (B)
Structural model of KIT-D816V cancer mutant. Structural change in KIT-D816V position and unwinding of the 310-helix are highlighted with arrows.
doi:10.1371/journal.pone.0007485.g008
Figure 9. Structural Modeling of the EGFR-L861Q Mutant. (A) The inactive, Src-like structure of EGFR (pdb entry 2G7). The position of L861 is
indicated with an arrow. The conserved salt bridge between K645 and E762 is broken in the inactive structure. (B) The model of the EGFR-L861Q
mutant displays the active-like conformation of the activation loop. The new position of EGFR-L861Q residue and the restored salt bridge between
K745 and E762 are indicated with arrows.
doi:10.1371/journal.pone.0007485.g009
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Figure 10. Protein Stability Analysis of the Cancer Mutation Hotspot. Protein stability differences calculated between the WT and mutants
for structurally conserved mutations using CUPSAT (A) and FOLDx approaches (B). Negative values of protein stability changes correspond to
destabilizing mutations.
doi:10.1371/journal.pone.0007485.g010
Figure 11. Protein Stability Analysis of KIT Mutations. Protein stability differences between the WT and mutants for a panel of KIT mutations
using CUPSAT (A) and FOLDx approaches (B). The panel included both disease-causing mutations and commonly occurring cancer mutations at D816
position. Negative values of protein stability changes correspond to destabilizing mutations.
doi:10.1371/journal.pone.0007485.g011
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mutations, we compared protein stability differences between
oncogenic KIT mutations at the D816 position and a spectrum
of disease-causing KIT variants (Figure 11). A considerable
destabilization effect on the autoinhibited inactive kinase was
observed for the activating KIT mutations. In contrast, disease-
causing SNPS only marginally affected protein stability of the WT
KIT structure. Despite simplified energy models employed in the
CUPSAT and FOLDx approaches, we observed consistent trends,
capturing highly oncogenic mutations as the mutations which elicit
larger and more detrimental protein stability changes. These
results are consistent with our earlier studies; supporting the
hypothesis that functional role of cancer mutations may be
associated with their impact on the protein kinase stability.
Discussion
Development of the integrated bioinformatics resource CKMD
has enabled structure-based functional annotation and prediction
of cancer mutation effects in protein kinases. Structural mapping
of kinase genetic variants onto aligned crystal structures and
mutational models has allowed to characterize molecular effects of
nsSNPs. We have found an enrichment of different categories of
SNPs in the different structural regions of the kinase domain,
suggesting structure-based determinants responsible for selection
of tumorigenic mutational hotspots. The distributions of nsSNPs
types has shown that (a) neutral kinase nsSNPs are randomly
distributed within the catalytic core; (b) disease-causing nsSNPs
map to regulatory and substrate binding regions; and (c) cancer-
causing nsSNPs can target catalytic and nucleotide binding
functions, preferentially clustering in the activation loop of the
kinase domain. Based on these results, we could speculate about
potential diversity of structural mechanisms that may be associated
with the effects of genetic alterations. It is possible that disease-
causing mutations may function by perturbing the local environ-
ment near the organizing F-helix, which is responsible for
maintaining structural plasticity and correct positioning of the
key catalytic and regulatory spine regions [85–87]. On the other
hand, structural effects of cancer-causing mutations may manifest
in perturbing flexible regions that are directly involved in
conformational transitions between inactive and active kinase
forms. The preferential localization of cancer-causing mutations in
the P-loop and the activation loop may lower the energetic barrier
for triggering the dynamic imbalance shifted towards the
constitutively active kinase conformation. The earlier analysis of
protein kinase motions indicated that conformational motions in
functionally important protein regions which harbor cancer
mutations, namely the P-loop and activation loop, are coupled
and may be highly correlated [56,57].
Although kinase cancer mutations may not exhibit a strong
sequence conservation signal, we have identified a number of
structurally equivalent positions within the protein kinase catalytic
core can be frequent targets of tumorigenic mutations. These
structurally conserved mutations tend to cluster into specific
mutational hotspots which may be shared by multiple kinase
genes. Sequence and structure-based methods were used to
characterize molecular determinants of mutational hotspots in
protein kinases. We have determined that structurally conserved
hotspots in the kinase catalytic domain can be often enriched by
cancer driver mutations with a high oncogenic potential.
Structural modeling and energetic analysis of the mutational
hotspots have also suggested a common molecular mechanism of
kinase activation by cancer mutations, which may be determined
by a combined effect of the partial destabilization of the inactive
state and a concomitant stabilization of the active-like form of the
enzyme. Furthermore, the results have indicated that cancer
mutations with the higher oncogenic potential can have a greater
differential effect on thermodynamic stability of the inactive and
active kinase forms. Structure-based computational prediction and
analysis of cancer mutation effects may thus be helpful for
integrative cancer biology studies exploring the molecular
pathology of tumorigenesis.
Ongoing development of database-oriented research tools
within the CKMD environment will allow for automated
structural and network-based bioinformatics analyses of rapidly
growing knowledge-base of resequencing data on protein kinase
genes. Further integration of genetic, functional, and structural
insights about the molecular basis of tumorigenesis into robust
bioinformatics infrastructure can ultimately help to discover
molecular signatures of cancer mutations.
Materials and Methods
The Database Content and Organization
CKMD was developed as a bioinformatics resource for
structure-functional analysis of genetic variations in protein
kinases. We employed MySQL as a relational database manage-
ment system for storing and managing the information content.
Perl, a widely used scripting language was used to parse the data
into various table forms. PHP5 Hypertext preprocessor was used
in the design of the database interface, while Apache was used as
the web server. Data stored in CKMD were mainly gathered from
NCBI [74–76], COSMIC [82], SwissProt [120–122], and
Protein Data Bank (PDB) [123]. We have also integrated non-
redundant information about genetic variations in protein kinases
from more specialized resources PupaSNP [73], KinMutBase
[77,78], BTKbase [79], HGMD [80,81], PKR [83], and
MoKCa [84].
Main entries in CKMD were indexed as genes and each gene
entry contained many sub-entries of related information associated
with that gene. We opted the gene id (GeneID) from Entrez Gene
database as the unique identifier to index all entries in CKMD.
This was partly due to the fact that the COSMIC database also
referenced to GeneID in its entries. SwissProt, however, did not
reference to GeneID and thus we developed a relation that
matched SwissProt accession numbers with GeneIDs. This
relation was crucial to coherently incorporate SwissProt data into
CKMD along with the data from other sources. The raw data
gathered from NCBI, SwissProt, and COSMIC were text files. All
MySQL tables in CKMD referenced to either GeneID or
SwissProt accession number. For each SNP entry, information
about its position, nucleotide change and corresponding amino
acid change was uniquely mapped on the protein kinase sequence
and structure. The main information sources and a general
architectural framework of CKMD are summarized in the design
diagrams (Figure S1).
CKMD provides a simple and intuitive user interface that
allows users to browse, search, download, and analyze genetic,
sequence, structure and functional data on protein kinase data
within a single integrated source. There are five main options
available in CKMD: Composite, Browse, Search, Download, and
Statistics. The ‘‘Composite’’ option offers a convenient and
transparent way to view all information stored in CKMD for
kinases genes. The ‘‘Browse’’ option allows to browse through
entries in CKMD in three major categories: Gene, Mutation, and
Structure. The ‘‘Search’’ option permits to query CKMD for a
particular entry using many different searching criteria. The
‘‘Download’’ option allows to download and view all available
protein kinase crystal structures and a large number of mutational
Cancer Mutation Hotspots
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models. Finally, the ‘‘Statistics’’ option offers various sequence and
structure-based statistical analyses of SNPs distributions across
kinase genes. The important CKMD functionality is that the
database stores and provides a convenient access to protein kinase
crystal structures and mutational models with the mapped nsSNPs.
A total of 989 crystal structures corresponding to 126 kinase genes
were collected from PDB and consolidated in CKMD. To
facilitate structure-functional analysis of genetic variations in
kinase genes, all crystal structures and mutational models were
structurally aligned using a java-based multiple alignment tool
STRAP (http://www.charite.de/bioinf/strap) and TM-align al-
gorithm [124]. We have developed Java applet using Jmol, an
open-source Java viewer for chemical structures in 3D (http://
www.jmol.org/), to provide graphical representation of protein
kinase structures. This interface could allow users to load and view
multiple and aligned protein kinase structures along with
convenient tools for manipulation of three-dimensional structures,
localization and molecular analysis of SNPs.
Protein kinase sequences were obtained from Kinbase (http://
kinase.com/kinbase/). Common SNPs were retrieved from
PupaSNP [73] and dbSNP [74] using the Ensembl data mining
tool, Biomart (http://www.ensembl.org/Homo_sapiens/martview).
The disease causing SNPs were retrieved from OMIM [75,76],
KinMutBase [77,78], and HGMD resources [80,81]. Currently,
there are 518 kinase gene entries in CKMD, both referenced in
NCBI [74–76] and SwissProt database [120–122], and 7955
unique SNP entries corresponding to these kinase genes that are
referenced in NCBI. These unique SNP entries include 3722
synonymous, 3985 missense, 75 nonsense and 173 frameshift
mutations. We have also gathered 780 OMIM variant entries from
NCBI and 3542 SwissProt variant entries. Cancer mutations were
retrieved from OMIM [75,76] and COSMIC resources [82]. The
complete lists of mRNA and protein products for each unique SNP
entry were also included and cross-linked to NCBI database. All
nsSNPs were assigned to positions in Kinbase protein sequence using
flanking sequences in the Ensembl and Entrez Gene sequences
because of higher confidence in Kinbase sequences versus other
publicly available sequences. Corresponding positions in DNA
sequences were determined using a combination of flanking
sequences given in dbSNP data and Genewise (http://www.ebi.ac.
uk/Wise2/).
Motif-based and Structure-based Multiple Sequence
Alignments
Motif-based alignments of kinase sequences to the catalytic core
were first generated by implementation of the Gibbs motif
sampling method [125,126]. This method identifies characteristic
motifs for each individual subdomain of the kinase catalytic core,
which are then used to generate high-confidence motif-based
Markov chain Monte Carlo multiple alignments based on these
motifs [127,128]. These subdomains define the core structural
components of the protein kinase catalytic core. Intervening
regions between these subdomains were not aligned. The nsSNPs
were then mapped to the kinase catalytic domain in accordance
with this alignment. Cancer driver predictions were performed by
using the SVM approach as described in our earlier work [70,71].
Sequence analysis was done with the aid of the subPSEC
conservation measure [88,89].
To further verify structural distribution of nsSNPs in functional
kinase regions, we also performed structure-informed multiple
alignment of kinase sequences using PROMALS3D approach
[129]. In this approach, 30 different kinase crystal structures
(Table S4) (the maximum allowed limit of structural information
used by PROMALS3D) and kinase catalytic domain sequences for
445 different genes were used for the multiple sequence alignment.
The obtained alignment was then matched against the alignment
of the kinase sequences with the available crystal structure to
ascertain the quality of the sequence alignment. The predicted and
observed residue ranges for the catalytic loop, hinge region, aC-
helix, activation loop and P-loop are in excellent agreement with
the observed residue ranges for these functional kinase regions
(Table S5).
Kinase SNP Distribution and Enrichment Analysis
Functionally important subdomains of the kinase catalytic core,
as in the nomenclature defined by Hanks and Hunter [7], were
examined to determine the distribution of nsSNPs and identify
structurally conserved hotspots of functionally important muta-
tions. The number of SNPs in each of the subdomains was
calculated from the structure-informed multiple sequence align-
ment described in the previous section. The expected probability
E(p) of a SNP occurring in a kinase subdomain region was
calculated separately for each SNP type as previously documented
[71,72]. In brief, the average length of each region was calculated
as the weighted average of the region length in each kinase
considered, where weights correspond to the total number of SNPs
occurring within each kinase. This weighting helps avoid biases
that might arise as a result of some kinases simply harboring more
SNPs than others. The probability of a SNP occurring within a
particular region purely by chance was computed as its weighted
average length over the sum of every region’s weighted average
length . The probability (p-value) of the observed total number (x)
of SNPs occurring within each region, where n is the total number
of SNPs considered, was calculated using the general binomial
distribution as follows:
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Structural Modeling and MD Refinement of Kinase
Cancer Mutants
We have also consolidated in CKMD all publically available
crystal structures of WT and mutant protein kinases from PDB. A
total of 989 kinase crystal structures corresponding to 126 genes
were deposited in CKMD. Although a number of kinase crystal
structures including mutants have been solved, there is still very
little structural information about most cancer kinase mutants. To
facilitate structure-functional analysis of cancer mutation effects in
protein kinases we have generated and stored in CKMD structural
models of a large number of protein kinase mutants (Figure S2).
Only a subset of all SNPs can be directly mapped onto the kinase
crystal structures. As a result, there are some protein kinases with
the known WT crystal structure and known SNPs, yet no
mutational models could be generated, because either all known
mutations reside outside of the resolved crystal structure of the
kinase catalytic domain or only synonymous mutations were
available.
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Structural modeling of nsSNPs was carried out using MOD-
ELLER [130,131] with a subsequent refinement of side-chains by
the SCRWL3 program [132]. Initial models were built in
MODELLER using a flexible sphere of 5 Å around mutated
residue and the inactive crystal structures of the WT EGFR,
FLT3, and KIT kinases as the templates. A protocol involving a
conjugate gradient (CG) minimization, followed by simulated
annealing refinement was repeated 20 times to generate 100 initial
models for each studied mutant. In the optimization stage, we
initially used 5000 steps of conjugate gradient (CG) minimization
to remove unfavorable contacts and ensure sufficient relaxation of
the local environment near mutational site. The predicted
mutational models were chosen out of the 100 models as scored
by the MODELLER default scoring function. These final models
were then refined in 2ns MD simulations using NAMD 2.6 [133]
with the CHARMM27 force field [134,135]and the explicit
TIP3P water model as implemented in NAMD 2.6 [136].
Equilibration was done in stages by gradually increasing the
system temperature in steps of 20K starting from 10K until 310K.
At each stage, 10,000 equilibration steps was employed, while
applying a harmonic restraining force of 10 Kcalmol21Å22 to all
backbone Ca atoms. Subsequently, the system was equilibrated for
150,000 steps at 310K (NVT) and then for additional 150,000
steps at 310K using Langevin piston (NPT) to maintain the
pressure. Finally the restrains were removed and the system was
equilibrated for 500,000 steps to prepare the system for simulation.
An NPT simulation was run on the equilibrated structure keeping
the temperature at 310K and pressure at 1 bar using Langevin
piston coupling algorithm. Nonbonded van der Waals interactions
were treated by using a switching function at 10A and reaching
zero at 12 Å distance.
Protein Stability Calculations
To quantify the destabilization effect of cancer mutations on the
inactive, autoinhibited kinase form, we computed the protein
stability change upon these mutations using CUPSAT (Cologne
University Protein Stability Analysis Tool) approach for the
prediction and analysis of protein stability changes upon point
mutations [137,138] and Foldx method [139,140]. In the
CUPSAT approach, coarse-grained atom potentials and torsion
angle potentials are used to predict protein stability upon point
mutations. Foldx analysis of protein stability is based on the
empirical force field which was developed for the rapid evaluation
of the effect of mutations on the stability, folding and dynamics of
proteins and nucleic acids. The free energy of folding is evaluated
in this approach from the difference in Gibbs free energy between
the crystal structure of the protein and a hypothetical unfolded
reference state of which no structural details are known.
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